Moderna’s mFlusiva Becomes First mRNA Flu Shot Cleared by FDA
FDA approves mFlusiva, Moderna’s first mRNA flu vaccine for adults 50+. Available soon for the 2026 season with strong trial results.
NOTRELOAD AI
Honeywell Aerospace Cuts 2026 Outlook as Supply-Chain Issues Persist After Spin-Off
Newly independent Honeywell Aerospace lowers 2026 sales growth to 4-5% and weakens EPS guidance as supply constraints limit aftermarket sales.
SoundHound Posts Record $61.9M Revenue, Raises 2026 Outlook as OASYS Fuels Growth
SOUN stock surged after posting record $61.9M Q2 revenue (up 45%), stronger margins, and raising full-year 2026 outlook to $230–$260 million.
IonQ Delivers Strongest Quarter Ever as Revenue Nearly Quadruples
IonQ reported record Q2 revenue of $80.1 million (up 287% YoY), beating forecasts. The quantum firm raised full-year guidance to $280–290M.
Duolingo’s Strong User Growth Overshadowed by Soft Revenue Outlook
Duolingo’s daily users jumped 23% to 58.7M in Q2, but soft Q3 revenue guidance of $302M missed estimates and sent shares down over 11%.
AppLovin Q2 Results: Solid Numbers, Soft Guidance, Sharp Sell-Off
Revenue rose 53% to $1.92B with solid profits, but a slight miss and soft Q3 guidance sparked the sell-off.